3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Neoplasms
1
Glioma
1
Glioblastoma
1
Brain Neoplasms
1
Astrocytoma
1
Interventions
Temozolomide
52
Radiotherapy
24
Bevacizumab
23
Radiation
10
Magnetic Resonance Spectroscopy
7
Lomustine
7
Carmustine
7
Radiosurgery
6
Surgical Procedures, Operative
5
Irinotecan
5
Aminolevulinic Acid
5
Radiotherapy, Intensity-Modulated
4
Nivolumab
4
Ipilimumab
4
Erlotinib Hydrochloride
4
Cilengitide
4
vocimagene amiretrorepvec
3
vitespin
3
sargramostim
3
poly ICLC
3
pembrolizumab
3
fluoromisonidazole
3
carmustine, poliferprosan 20 drug combination
3
Vorinostat
3
TPI-287
3
O(6)-benzylguanine
3
Granulocyte-Macrophage Colony-Stimulating Factor
3
Flucytosine
3
Dynamic Contrast Enhanced Magnetic Resonance Imaging
3
Drug Therapy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Glioblastoma
×
Trabedersen
×
Clear all
NCT00761280
2014-11-14
SAPPHIRE
Isarna Therapeutics GmbH
Phase 3
Terminated
27 enrolled
28 charts